Novartis’s Iptacopan (LNP023) Receives EMA’s Prime Designation for C3 Glomerulopathy

 Novartis’s Iptacopan (LNP023) Receives EMA’s Prime Designation for C3 Glomerulopathy

Novartis’s Iptacopan (LNP023) Receives EMA’s Prime Designation for C3 Glomerulopathy

Shots:

  • EMA has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME designation enhancing the development of medicine targeting unmet medical need. Results of P-II interim analysis for iptacopan in C3G will be presented at ASN 2020
  • Additionally, the company is investigating iptacopan in P-III study in PNH patients with residual anemia despite treatment with anti-C5 Ab therapy, planned to initiate in Dec’2020. The P-II data in PNH presented at EBMT
  • Iptacopan is an oral, small-molecule, reversible inhibitor of factor B and has received FDA’s & EMA’s ODD in C3G, based on the preliminary data from the ph2 trial

    Click here ­to­ read full press release/ article | Ref: Novartis | Image: BioProcess International

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post